美索比妥
|
|
- CAS号:
- 151-83-7
- 英文名:
- Methohexital
- 英文别名:
- Brietal;Brevital;Methhexital;METHOHEXITAL;Methohexitone;compound22451;Compound 22451;Compound 25398;Methodrexitone;Methohexital solution
- 中文名:
- 美索比妥
- 中文别名:
- 美索比妥;5-烯丙基-1-甲基-5-(1-甲基-2-戊炔基)巴比妥酸
- CBNumber:
- CB1492534
- 分子式:
- C14H18N2O3
- 分子量:
- 262.3
- MOL File:
- 151-83-7.mol
|
|
|
美索比妥化学性质
-
熔点:
-
96 °C(Solv: ethanol (64-17-5))
-
|
-
密度:
-
1.113
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
7.82±0.10(Predicted)
-
|
-
颜色:
-
White to Off-White
-
|
-
NIST化学物质信息:
-
Methohexitone(151-83-7)
-
|
美索比妥性质、用途与生产工艺
1.诱导麻醉剂。
2.用于手术可减小疼痛的刺激。
3.可做为其他麻醉剂辅助。
4.诱导安眠状态。
本品为静脉注射的麻醉剂。静脉注射后很快就被脑组织吸收,且迅速在身体的其他部位重新分布。
本品的起始作用非常迅速(30s),作用期非常短暂(5~10min)在体内很快就重新分布,经由肾脏缓慢排出.在脂肪组织的积蓄很显著。
1.重复或连续注射可能造成积蓄,导致作用延长和严重的心血管和呼吸抑制。通常应有必备的抢救设备(如气管内套管,氧气)。
2.孕妇或虚弱病人,如哮喘连续发作,循环、呼吸、肾、肝或内分泌功能受损的病人等使用本品立小心。
3.不要用乳化生理盐水稀释。
呼吸抑制,中度的低血压和打嗝。此外.还有头痛,呕吐,谵妄,肌肉抽搐,喉咙痉挛,支气管痉挛,血栓性静脉炎,过敏反应(包括瘙痒,荨麻疹,鼻炎,呼吸急促),腹痛等。
用法与用量:1.诱导剂量:5~12ml 1%的溶液,以1ml/5s的速率静脉注射。维持剂量:2ml至4ml1%的溶液,每4~7分钟给药1次(连续滴注0.2%,每秒1滴)。
http://baike.baidu.com/link?url=WCyTYN0i6owPzRzbQB4IZ1vFF-lCvznDLkKswTRTZnfZmp6kfKNhkiWn4jajl7-Da4_1MqFc9uGSC1KvbZBCFFQ3ahLInXMi99wlb7Eb7ocLmvHfbdaOxL8g9kf7C9xY
http://www.med126.com/pharm/2011/20110330020008_436417.shtml
用途
短效麻酔药
美索比妥
上下游产品信息
上游原料
下游产品
美索比妥
生产厂家
全球有 52家供应商
美索比妥国内生产厂家
151-83-7, 美索比妥 相关搜索:
- Pharmaceuticals
- Neurochemicals
- Intermediates & Fine Chemicals
- Heterocycles
- C14H18N2O3
- 美索比妥
- 5-烯丙基-1-甲基-5-(1-甲基-2-戊炔基)巴比妥酸
- 151-83-7
- Methohexital (Mixture of Diastereomers) (1.0mg/ml in Acetonitrile)
- Methohexital (Mixture of Diastereomers)
- (18652-93-2) methohexital
- Methodrexitone
- DL-1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
- compound22451
- Compound 25398
- Compound 22451
- Brietal
- Brevital
- Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, (.+/-.)-
- Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, (±
- Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-
- 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
- 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (.+/-.)-
- 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (±
- 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-
- METHOHEXITAL
- 1-Methyl-5-(1-methylpent-2-ynyl)-5-prop-2-enyl-hexahydropyrimidine-2,4,6-trione
- α-DL-1-methyl-5-allyl-5-(1-methylpentyn-2-yl)barbituricacid
- 1-Methyl-5-(1-Methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-2,4,6(1H,3H,5H)-pyriMidinetrione
- Methhexital
- Methohexital CIV (500 mg)
- 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
- 5-allyl-1-methyl-5-(1-methylpent-2-ynyl)barbituric acid
- 5-(1-Methyl-2-pentynyl)-1-methyl-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
- 1-Methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)barbituric acid
- Methohexitone
- Methohexital solution
- 2,4,6(1H,3H,5H)-PyriMidinetrione,1-Methyl-5-(1-Methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-